Treatment options for patients with dedifferentiated liposarcoma (DDLS) remain limited, and currently available therapies provide only modest disease control. Targeting CDK4, which is commonly amplified in DDLS, has emerged as a rational therapeutic strategy. The phase 3 SARC041 trial evaluated whether the CDK4/6 inhibitor abemaciclib could improve outcomes in patients with advanced or metastatic disease.
A total of 108 patients with progressive DDLS were randomized to receive abemaciclib or placebo, with crossover to abemaciclib allowed after disease progression. At the time of analysis, abemaciclib was associated with a marked improvement in progression-free survival (PFS). Median PFS was 9.7 months compared with 1.5 months with placebo (hazard ratio [HR], 0.39), representing a substantial delay in disease progression.
Objective response rates remained modest (9.3% vs 0%), consistent with the largely cytostatic mechanism of CDK4 inhibition; however, prolonged disease stabilization contributed to the substantial PFS benefit observed with abemaciclib.
An encouraging trend in overall survival (OS) was observed, with median OS not yet reached in the abemaciclib arm compared with 25.5 months in the placebo arm (HR, 0.55), although the study was not powered to demonstrate a statistically significant OS benefit. Interpretation of OS outcomes may be influenced by the trial’s crossover design, which allowed patients assigned to placebo to receive abemaciclib after disease progression.
The safety profile was consistent with the known safety profile of abemaciclib, with no new safety signals identified.
These findings suggest that abemaciclib may offer a meaningful new treatment option in advanced DDLS, particularly in a setting where therapeutic choices are limited. The nearly 8-month improvement in median PFS represents one of the largest benefits reported in a randomized study of advanced DDLS.
Although OS data remain immature, CDK4 inhibition represents a clinically relevant addition to the treatment landscape for DDLS.
Source: Dickson MA, Ballman KV, Weiss MC, et al. SARC041: phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. Presented at: ASCO Annual Meeting. May 29-June 2, 2026; Chicago, IL. Abstract LBA2.